<PAGE>
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from -------------------- to --------------------
Commission File Number
ALGOS PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
Delaware 22-3142274
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
</TABLE>
1333 Campus Parkway, Neptune, New Jersey, 07753-6815
(Address of principal executive offices)
732-938-5959
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports) and has been subject to such filing requirements for the
past 90 days. Yes X No
--- ---
The aggregate number of shares of the Registrant's common stock outstanding on
April 23, 1999 was 17,353,545.
<PAGE>
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
December 31, March 31,
1998 1999
---- ----
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $37,025,445 $28,529,862
Marketable securities, current 9,001,528 13,888,702
Interest receivable 417,042 268,203
Prepaid expenses and other current assets 683,866 629,456
----------- -----------
Total current assets 47,127,881 43,316,223
Marketable securities, noncurrent 4,052,824 4,042,709
Restricted cash 150,000 150,000
Property and equipment, net 1,098,819 1,152,266
----------- -----------
Total assets $52,429,524 $48,661,198
----------- -----------
----------- -----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,117,795 $ 3,561,978
Other current liabilities 794,044 741,696
----------- -----------
Total current liabilities 2,911,839 4,303,674
----------- -----------
Commitments
Stockholders' equity:
Common stock, $.01 par value, 50,000,000 shares
authorized, 17,028,649 and 17,353,045 shares
issued and outstanding, respectively 170,287 173,531
Additional paid-in-capital 81,626,800 81,781,877
Unearned compensation expense (611,108) (519,010)
Deficit accumulated during the development stage (31,668,294) (37,078,874)
----------- -----------
Total stockholders' equity 49,517,685 44,357,524
----------- -----------
Total liabilities and stockholders' equity $52,429,524 $48,661,198
----------- -----------
----------- -----------
</TABLE>
The accompanying notes are an integral part of these financial statements.
1
<PAGE>
<PAGE>
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
For the three months ended Cumulative
March 31, from inception
-------------------------------- to March 31,
1998 1999 1999
---- ---- ----
<S> <C> <C> <C>
Revenues $ - $ - $ 3,311,000
--------------- ---------------- ----------------
Operating expenses:
Research and development 3,220,459 2,516,989 31,179,119
Selling, general and administrative 741,532 3,462,049 15,388,576
--------------- ---------------- ----------------
Total operating expenses 3,961,991 5,979,038 46,567,695
--------------- ---------------- ----------------
Loss from operations (3,961,991) (5,979,038) (43,256,695)
Interest income 564,189 568,458 6,177,821
--------------- ---------------- ----------------
Net loss $ (3,397,802) $ (5,410,580) $(37,078,874)
=============== ================ ================
Net loss per common share, basic and diluted $ (0.21) $ (0.31)
=============== ================
Weighted average common
shares, outstanding basic and diluted 15,955,367 17,299,134
=============== ================
</TABLE>
The accompanying notes are an integral part of these financial statements
2
<PAGE>
<PAGE>
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
For the three months ended Cumulative
March 31, from inception
-------------------------------- to March 31,
1998 1999 1999
---- ---- ----
<S> <C> <C> <C>
Cash flows from operating activities $ (3,011,963) ($3,706,149) $(31,267,627)
Cash flows from investing activities:
Investment in marketable securities (15,035,672) (9,842,358) (76,753,015)
Redemption of marketable securities 7,968,575 5,000,000 58,853,072
Purchases of property and equipment (69,430) (105,397) (1,508,992)
----------------- ---------------- ------------------
Net cash used in investing activities (7,136,527) (4,947,755) (19,408,935)
----------------- ---------------- ------------------
Cash flows from financing activities:
Proceeds from issuance of preferred stock 6,659,015
Proceeds from issuance of common stock 123,126 158,321 72,547,409
----------------- ---------------- ------------------
Net cash provided by financing activities 123,126 158,321 79,206,424
----------------- ---------------- ------------------
Net increase (decrease) in cash and cash equivalents (10,025,364) (8,495,583) 28,529,862
Cash and cash equivalents, beginning of period 20,246,152 37,025,445 -
----------------- ---------------- ------------------
Cash and cash equivalents, end of period $ 10,220,788 $ 28,529,862 $ 28,529,862
================= ================ ==================
</TABLE>
The accompanying notes are an integral part of these financial statements.
3
<PAGE>
<PAGE>
ALGOS PHARMACEUTICAL CORPORATION
(A Development Stage Enterprise)
NOTES TO FINANCIAL STATEMENTS
(Unaudited)
1. BASIS OF PRESENTATION
The financial statements presented herein have been prepared in accordance
with generally accepted accounting principles for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X and are
unaudited. In the opinion of management, the financial statements reflect all
adjustments (which consist of normal recurring accruals and adjustments)
necessary for a fair statement of the financial position and results of the
interim periods presented.
2. LOSS PER SHARE
Since the Company incurred net losses in all periods presented, outstanding
options and warrants to purchase an aggregate of 1,060,455 and 1,508,481 shares
of Common Stock at March 31, 1998 and 1999, respectively, were not included in
diluted per share calculations, as their effect would be antidilutive.
4
<PAGE>
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
General
Algos, a development stage company, is engaged primarily in the development
and commercialization of proprietary pharmaceutical products. Since its
formation in January 1992, the Company has devoted a substantial amount of its
efforts to licensing technology, recruiting key management and staff, developing
products, filing patents and other regulatory applications and raising capital.
The Company has incurred losses since its inception and expects to incur
losses in the future. The Company's product development expenses may increase as
additional drugs are developed. In August 1998, the Company filed a New Drug
Application (NDA) for its most developmentally advanced drug, MorphiDex'r'. The
Company may incur significant costs associated with the possible
commercialization of MorphiDex'r' prior to the first commercial sale of the
product, including the purchase of inventory, the establishment of a sales
force, the preparation of promotional plans and materials, additions to and
changes in financial and operating systems, and other related administrative
expenses.
Results of Operations
Three months ended March 31, 1998 and 1999
Research and development:
In the three months ended March 31, 1999, research and development expenses
were $2.5 million, a decrease of approximately $700,000, or 22%, from 1998. In
1999, expenses decreased due to the impact in 1998 of large-scale, advanced
clinical trials and toxicology studies of MorphiDex'r' and the conduct of
formulation and manufacture of HydrocoDex'TM'clinical supplies. These effects
were offset by expenses related to Phase II clinical studies of HydrocoDex'TM'
in 1999.
Selling, general and administrative:
In the three months ended March 31, 1999, selling, general and
administrative expenses were $3.5 million, an increase of $2.7 million from
1998. The significant increase was primarily attributable to the possible future
commercialization of products including fees to sales and marketing consultants,
educational materials and activities, and the addition of marketing personnel,
as well as the general expansion of the Company's business activities.
Liquidity and Capital Resources
As a result of its drug development efforts, the Company has experienced
net cash outflows from operations since its inception in 1992. In the three
months ended March 31, 1999, cash outflows from operations amounted to
approximately $3.7 million compared to $3.0 million in the first quarter of
1998, primarily as a result of its increased expenses related to the possible
commercialization of MorphiDex'r'.
The Company intends to continue certain pre-commercialization activities
and ongoing large-scale clinical trials for MorphiDex'r' in 1999 and has entered
into several research and development commitments for HydrocoDex'TM'. The
Company expects to incur product development expenses as clinical
trials of MorphiDex'r' continue and other drugs that the Company currently has
under development, including HydrocoDex'TM' move into advanced clinical trials
and as additional drugs are developed and research and development staff
increased. In August 1998, the Company filed an NDA for MorphiDex'r'. Algos may
incur significant costs associated with the possible commercialization of
MorphiDex'r' prior to the first commercial sale of
5
<PAGE>
<PAGE>
the product, including the purchase of inventory, the establishment of a sales
force, the preparation of promotional plans and materials, additions to and
changes in financial and operating systems and other related administrative
expenses. The Company currently expects that its cash and marketable securities
at March 31, 1999 will be sufficient to fund its development activities for
approximately two years and provide for certain pre-launch activities based
upon the Company's current schedule of clinical trials and level of business
activities. However, if a significant portion of existing funds is required
in the preparation for the possible commercialization of MorphiDex'r', or if
additional trials are necessary or advisable, or if additional products are
developed, the Company may require additional funds. In the event that revenue
and income from successful product introductions or other internally generated
funds are insufficient for such efforts, the Company will need to raise
additional funds either by incurring debt, issuing additional equity or
through collaborative or license arrangements to ensure continuity of
operations. There is no assurance that the Company would be able to obtain
such additional financing on terms acceptable to the Company.
The Company's future funding requirements will depend on a number of
factors, including: the amount of resources required for the establishment of
sales and distribution capabilities; the preparation of promotional plans and
materials and other activities in preparation for the possible commercialization
of MorphiDex'r'; the results of its development efforts; the timing and costs of
obtaining required regulatory approvals; the commercialization of competing
products; the execution of licensing or other collaborative research agreements
on terms acceptable to the Company; and the cost of prosecuting and defending
patents.
Year 2000
A potential problem exists for all companies that rely on computers as the
year 2000 approaches. Any of Algos' computer software applications and systems
that use only the last two digits of a year to refer to a year may not properly
recognize the year 2000. This phenomenon (the Year 2000 Issue) could cause a
disruption of operations, including, among other things, a temporary inability
to engage in normal business activities.
Algos is in the process of evaluating the impact of the Year 2000 Issue and
currently believes that the financial and operational systems of Algos, as
currently used, will function adequately with respect to the Year 2000 Issue
given that Algos is not significantly reliant on its computer software
applications and systems during its developmental stage. However, if certain
data management and statistical applications do not function properly, the
analysis and reporting of study results could be delayed and the timing of
subsequent development activities and regulatory filings adversely affected. In
addition, Algos has very limited information concerning the compliance status of
its third-party contractors. Algos' current third party contractors generally
test Algos products and provide Algos with the results of those tests. Algos
believes that any Year 2000 Issue for such third-party contractors would not be
material, since many activities could be performed without the aid of a
computer. As part of the commercialization of MorphiDex'r', Algos intends to
have third parties manufacture and distribute its products. Algos will place
significant dependence on the third parties' computer systems for purchasing,
production, customer order entry and invoicing and other related activities. A
disruption in these systems could result in lost revenue from inventory
shortages, improper execution of customer orders and/or delays in the resolution
and collection of outstanding invoices. Algos will evaluate each potential
third-party manufacturer's and distributor's readiness for the Year 2000 Issue
and will reevaluate the Year 2000 Issue as it relates to Algos as part of its
preparation for the commercialization of MorphiDex'r'. Algos has filed an NDA
for MorphiDex'r' and may make significant additions to and changes in its
existing computer software applications and systems and/or the use of such
systems in anticipation of the possible commercialization of MorphiDex'r'. If
Algos makes any such additions or changes, it would affect Algos' exposure to
the Year 2000 Issue since Algos would become more reliant on its computer
software applications and systems. Therefore, Algos' assessment of its Year 2000
Issue is not complete and Algos cannot complete its assessment or develop any
contingency plans until mid-1999.
6
<PAGE>
<PAGE>
At this time, Algos does not expect that the cost of its Year 2000 Issue
compliance program will be material to its business, financial condition or
results of operations and does not currently anticipate any material disruption
in its operations. Algos has not incurred more than $10,000 of costs to date
related to the Year 2000 Issue.
Forward Looking Statements
This Report contains "forward-looking" statements, within the meaning of
Section 27A of Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, that are based on management's beliefs and
assumptions, current expectations, estimates and projections. Statements that
are not historical facts, including statements which are preceded by, followed
by, or that include the words "believes;" "anticipates;" "plans;" "expects;" or
similar expressions and statements about the Company's development or
commercialization schedules and future use of funds are forward-looking
statements. Many of the factors that will determine the Company's future
results are beyond the ability of the Company to control or predict. These
statements are subject to risks and uncertainties and, therefore,
actual results may differ materially. The reader should not rely on any
forward-looking statement. The Company undertakes no obligations to update any
forward-looking statements whether as a result of new information, future events
or otherwise. Important factors that may affect future results include, but are
not limited to: uncertainty associated with pre-clinical studies and clinical
trials and regulatory approval; uncertainty of market acceptance of new
products; impact of competitive products and pricing; product development;
changes in laws and regulations; customer demand; possible future litigation;
the availability of future financing and reimbursement policies of government
and private health insurers and others. Readers should evaluate any statement in
light of these important factors. See "Risk Factors".
7
<PAGE>
<PAGE>
Item 6. Exhibits and Reports on Form 8-K
(3) Exhibits:
<TABLE>
<CAPTION>
Exhibit
No. Title
- ------- ----------------------------------------------------
<S> <C>
1.1 --Purchase and Registration Rights Agreement, dated as of November 9, 1998(6)
3.1 --Amended and Restated Certificate of Incorporation of Algos
Pharmaceutical Corporation(1)
3.2 --Amended and Restated By-laws of Algos Pharmaceutical Corporation(1)
4.1 --Form of Stock Certificate of Common Stock(1)
4.2 --Warrant to Purchase 250,000 Shares of Common Stock of Algos
Pharmaceutical Corporation and Biotech Target S.A., a Panamanian
corporation, dated November 9, 1998(6)
5.1 --Opinion of Latham & Watkins as to the validity of the Common Stock(1)
10.1.1 --Employment Agreement with Respect to John W. Lyle(4)
10.1.3 --Employment Agreement with Respect to Frank S. Caruso(1)
10.1.4 --Employment Agreement with Respect to Joseph Sardella(5)
10.2.1 --1994 Stock Option Plan(1)
10.2.2 --1996 Stock Option Plan(1)
10.2.3 --1996 Non-Employee Director Stock Option Plan(2)
10.3.1 --Algos Pharmaceutical Corporation Stockholders' Agreement(1)
10.4.1 --License Agreement with The Medical College of Virginia(1)(A)
10.4.2 --License Agreement with McNeil Consumer Products Company(1)(A)
10.4.3 --Registration Rights Agreement with The Medical College of Virginia(1)
10.5 --Lease Agreement with Commercial Realty & Resources Corp.(3)
21 --Subsidiaries of the Registrant(1)
27 --Financial Data Schedule, March 31, 1999
99 --Risk Factors
</TABLE>
(1) Incorporated by reference to the Registrant's registration statement on Form
S-1 declared effective on September 25, 1996.
(2) Incorporated by reference to the Registrant's Annual Report on Form 10-K for
the year ended December 31, 1996.
(3) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 1997
(4) Incorporated by reference to the registrant's Annual Report on Form 10-K for
the year ended December 31, 1997.
(5) Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q
for the quarterly period ended June 30, 1998.
(6) Incorporated by reference to the Registrant's registration statement on Form
S-3 dated March 10, 1999.
(A) Portions of this Exhibit have received confidential treatment pursuant to
Rule 406(b) under the Securities Act.
8
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALGOS PHARMACEUTICAL CORPORATION
Date May 14, 1999 /s/ John W. Lyle
---------------- ----------------------------------------
John W. Lyle
President and Chief Executive Officer
Date May 14, 1999 /s/ Gary R. Anthony
---------------- ----------------------------------------
Gary R. Anthony
Chief Financial Officer and Principal
Accounting Officer
9
STATEMENT OF DIFFERENCES
------------------------
The trademark symbol shall be expressed as............................. 'TM'
The registered trademark symbol shall be expressed as.................. 'r'
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 28,529,862
<SECURITIES> 13,888,702
<RECEIVABLES> 268,203
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 43,316,223
<PP&E> 1,508,992
<DEPRECIATION> 356,726
<TOTAL-ASSETS> 48,661,198
<CURRENT-LIABILITIES> 4,303,674
<BONDS> 0
<COMMON> 173,531
0
0
<OTHER-SE> 44,183,993
<TOTAL-LIABILITY-AND-EQUITY> 48,661,198
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 5,979,038
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (5,410,580)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (5,410,580)
<EPS-PRIMARY> (.31)
<EPS-DILUTED> (.31)
<PAGE>
<PAGE>
EXHIBIT 99
RISK FACTORS
Algos operates in a rapidly changing environment that involves a number of
risks that may significantly affect Algos' results, some of which are beyond
Algos' control. The following discussion highlights some of these risks, and
others are discussed elsewhere in other documents filed by Algos with the
Securities and Exchange Commission.
IF WE ARE UNABLE TO DEVELOP A MARKETABLE PRODUCT FROM WHICH WE CAN DERIVE
REVENUES, WE ARE UNLIKELY TO ACHIEVE PROFITABILITY.
We have no revenues from product sales and no history of commercial
manufacturing or marketing. To date, substantially all of our funding has been
provided by contributions of capital made by our founders, sales of our stock
and payments received under a license agreement with McNeil Consumer Products
Company with whom we are working to develop an over-the-counter pain reliever.
As a result, we have experienced losses since our inception and losses are
continuing and are expected to continue.
We have a limited history upon which you may base an evaluation of our likely
performance and there is a risk that we will not be able to develop a marketable
product and/or achieve profitability. Algos' prospects must be considered in
light of the potential problems, expenses, complications and delays encountered
in connection with the formation of a new business and the development of new
pharmaceutical products, including obtaining the necessary regulatory approvals,
the utilization of unproven technology and the competitive market environment in
which Algos plans to operate.
IF WE ARE UNABLE TO ADEQUATELY DEMONSTRATE THE SAFETY AND EFFECTIVENESS OF OUR
PRODUCTS IN HUMANS, WE MAY NOT BE ABLE TO PROCURE NECESSARY REGULATORY APPROVALS
TO BRING OUR PRODUCTS TO MARKET.
In order to receive regulatory approval to sell our products, Algos must
demonstrate that our potential products are safe and effective in humans.
Although the results of Algos' trials to date have been encouraging, the results
are not by themselves predictive of results that will be obtained from
subsequent or more extensive trials. Furthermore, there can be no assurance that
clinical trials of products under development will demonstrate the safety and
efficacy of such products to the extent necessary to obtain regulatory
approvals. Many pharmaceutical companies have suffered significant setbacks in
advanced clinical trials, even after promising results in earlier trials.
Therefore, there is a risk that we may fail to adequately demonstrate the safety
and efficacy of our products which could delay or prevent regulatory approval of
our products and prevent them from being sold.
The speed with which we complete our clinical trials is dependent upon, among
other factors, the ability to locate and enroll suitable patients at acceptable
facilities. Accordingly, delays in planned patient enrollment in Algos' current
trials or future clinical trials may result in increased costs, program delays
or both, which may delay the ability of Algos to begin generating revenues.
We currently do not have regulatory approval to sell any products. The FDA
and comparable agencies in foreign countries impose substantial requirements on
the introduction of pharmaceutical products through lengthy and detailed
laboratory and clinical testing and other costly and time-consuming procedures.
Satisfaction of these requirements typically takes a number of years and varies
substantially based upon the type, complexity and novelty of the pharmaceutical
products. There can be no assurance that if clinical trials are completed, Algos
will be able to submit a New Drug Application or
1
<PAGE>
<PAGE>
that any such application will be reviewed and approved by the FDA in a timely
manner, or at all. Government regulation also affects the manufacture and
marketing of pharmaceutical products. Regulatory approvals, if granted, may
include significant limitations on the indicated uses for which a product may be
marketed, which may reduce the size of the market for Algos' product. See
"Business--Government Regulation" in Algos' 1998 Annual Report on Form 10-K/A.
IF ALGOS PRODUCTS ARE NOT ACCEPTED BY THE MARKET, ALGOS WILL NOT BE ABLE TO
ACHIEVE PROFITABILITY.
Even if regulatory approvals are obtained and Algos products prove to be
superior to alternative products on the market, uncertainty exists as to Algos'
ability, or the length of time required, to achieve market acceptance of Algos
products. A number of factors may limit the market acceptance of Algos products,
including:
the availability of alternative products with greater name and brand
recognition than Algos,
the price of Algos products relative to alternative products,
the availability of third-party reimbursement and
the extent of marketing efforts by third-party distributors or agents
retained by Algos.
Furthermore, some of the Algos products contain opioid ingredients that may
require stringent record-keeping obligations, strict storage requirements and
other limitations on such products' availability that could limit the
distribution and commercial usage of such products. In light of these factors,
there is a significant risk that Algos will not be able to gain market
acceptance for its products which may prevent us from achieving profitability.
OUR SUBSTANTIAL RELIANCE ON THE CAPITAL MARKETS IN ORDER TO MEET OUR FINANCIAL
REQUIREMENTS MAY BE DILUTIVE OF THE VALUE OF ALGOS COMMON STOCK AND MAY IMPEDE
OUR ABILITY TO DEVELOP AND COMMERCIALIZE OUR PRODUCTS.
As a development stage company, Algos requires substantial amounts of funding
for its research and product development programs, operating expenses,
regulatory approvals and sales and marketing expenses, and no assurance can be
given that development and commercialization costs will not exceed the amounts
budgeted for such purposes. Because we do not currently generate any revenues
from product sales, we are dependent on our existing cash and our ability to
raise additional capital in order to fund our operations until we can begin
marketing our products. Any material delay in the marketing of our products may
require us to raise additional capital. Algos has limited financial resources
and its substantial reliance on the capital markets to satisfy its financial
requirements may dilute the value of Algos common stock. Conversely, if Algos is
unable to obtain sufficient funds through the financial markets or through
collaborative or other arrangements on a timely basis, there is a risk that
Algos may be required to delay, scale back or eliminate certain of its research,
development or commercialization programs or to make arrangements with third
parties to develop or commercialize products or technologies that Algos would
otherwise seek to develop or commercialize itself. In the event this occurs,
Algos may not be able to independently develop or commercialize any or all of
its products.
2
<PAGE>
<PAGE>
IF ALGOS IS UNABLE TO SUCCESSFULLY MARKET AND SELL OUR PRODUCTS, WE MAY BE
FORCED TO LICENSE OUR PRODUCTS TO OTHERS WHICH WILL HAVE AN ADVERSE EFFECT ON
ALGOS' PROFITABILITY.
Algos intends to market and sell some or all of its products, if successfully
developed and approved, through a direct sales force in the United States.
However, Algos currently has limited marketing and sales staff, and has yet to
establish any product distribution channels. If we are unable to develop a sales
force with technical expertise or to establish appropriate distribution
channels, we may be forced to license products we have developed to third
parties instead of directly marketing them which may reduce our profitability.
IF ALGOS IS UNABLE TO ACQUIRE SUFFICIENT SUPPLIES FROM THIRD PARTIES, THEN
ALGOS' ABILITY TO DELIVER OUR PRODUCTS TO THE MARKET MAY BE IMPEDED.
Algos currently uses, and expects to continue to use, outside contractors to
manufacture drug supplies for its clinical trials. In addition, Algos currently
intends to use outside contractors to manufacture products approved for sale, if
any. There is no assurance that Algos will be able to obtain its requested
amounts of drugs from these contractors or that supplies will not be interrupted
due to FDA and/or Drug Enforcement Agency, the DEA, regulatory requirements or
other reasons. If Algos cannot obtain a sufficient supply of ingredients or
supplies are interrupted, this may have a material adverse effect on our
reputation in the marketplace and our ability to develop and commercialize our
products.
For instance, Algos currently uses a single contract manufacturer for
supplies of its most developmentally advanced product, MorphiDex'r', and
suppliers of raw materials are limited. The regulatory qualification of
additional suppliers and/or manufacturers may require significant time and
expense. In addition, the acquisition of opioid ingredients as components of
certain Algos products is subject to quota restrictions imposed and administered
by the DEA. Accordingly, there is a risk that Algos will be unable to obtain its
requested quantities of opioid ingredients which could be detrimental to Algos'
ability to bring its product to market.
IF ALGOS IS UNABLE TO ATTRACT AND RETAIN QUALIFIED PERSONNEL, WE MAY NOT BE ABLE
TO MAINTAIN OUR COMPETITIVE POSITION.
Because of the specialized scientific nature of Algos' business, we are
highly dependent upon our ability to attract and retain qualified scientific and
technical personnel. The loss of significant scientific and technical personnel
or the failure to recruit additional key scientific and technical personnel
could have a material adverse effect on Algos' ability to develop and deliver
our products to market in a competitive manner. While Algos has consulting
agreements with certain key individuals and institutions and has employment
agreements with certain key executives, there can be no assurance that Algos
will be successful in retaining such personnel or their services under existing
agreements. The loss of John Lyle, Algos' Chief Executive Officer, could have a
material adverse effect on Algos because of the loss of Mr. Lyle's expertise and
because we would need to expend time and financial resources to seek a new Chief
Executive Officer which would materially slow our efforts to develop and
commercialize our products. Algos currently maintains a $6.0 million life
insurance policy on Mr. Lyle. There is intense competition for qualified
personnel in the areas of Algos' activities, and there can be no assurance that
Algos will be able to continue to attract and retain the qualified personnel
necessary for the development of its business.
IF WE ARE UNABLE TO PATENT OUR TECHNOLOGY OR ARE FOUND TO HAVE VIOLATED OR
INFRINGED ON THE PATENTS OF OTHERS, THIS WOULD ADVERSELY AFFECT OUR ABILITY TO
3
<PAGE>
<PAGE>
GENERATE REVENUES AND WE MAY NOT BE ABLE TO RECEIVE AN APPROPRIATE RETURN ON
OUR INVESTMENT.
Algos' policy is to seek patent protection and enforce intellectual property
rights. However, no assurance can be given that any patents will be allowed or
will provide protection against competitive products or otherwise be
commercially viable. In this regard, the patent position of pharmaceutical
compounds and compositions is particularly uncertain. Because we are a
development stage company without brand name recognition for our products, our
ability to successfully patent and protect the technologies we are developing or
may develop in the future is especially crucial to our ability to generate
future revenues and maintain our competitive position. However, there is a risk
that Algos' pending patent applications may not be allowed, or if they are
allowed, that the scope of the claims allowed will be insufficient to protect
Algos products. Furthermore, even issued patents may later be modified or
revoked by the United States Patent and Trademark Office, the PTO, or in legal
proceedings. Any of these outcomes would reduce future revenues and the return
on any investment in Algos.
In addition, no assurance can be given as to whether Algos will be able to
avoid violating or infringing upon patents issued to others. If Algos were found
to be infringing on a patent held by another, Algos might have to seek a license
to use the patented technology. There can be no assurance that, if required,
Algos would be able to obtain such a license on terms acceptable to Algos, if at
all. If a legal action were to be brought against Algos or its licensors or
licensees, Algos could incur substantial costs in defending itself, and there
can be no assurance that such an action would be resolved in Algos' favor. If a
patent infringement dispute were to be resolved against Algos, Algos could be
subject to significant damages and the manufacture or sale of one or more of
Algos' technologies or proposed products, if developed, could be stopped.
IF THIRD-PARTY REIMBURSEMENT FOR OUR PRODUCTS IS UNAVAILABLE OR INADEQUATE, WE
MAY NOT BE ABLE TO REALIZE AN APPROPRIATE RETURN ON OUR INVESTMENT AND/OR THE
MARKET ACCEPTANCE OF OUR PRODUCTS COULD BE ADVERSELY AFFECTED.
Algos' ability to commercialize its pain management products may depend in
part on the extent to which reimbursement for the costs of such products will be
available from government health administration authorities, private health
insurers and others. Government, private insurers and other third-party payers
are increasingly attempting to contain health care costs by limiting both
coverage and the level of reimbursement for new products approved for marketing
by the FDA and by refusing, in some cases, to provide any coverage for uses of
approved products for indications for which the FDA has not granted marketing
approval. Because we are developing a drug that may have higher costs than
generic alternatives that are currently available, there is a risk that insurers
will be unwilling to provide coverage for our product. If adequate coverage and
reimbursement levels are not provided by government and third-party payers for
uses of Algos products, the market acceptance of our products could be adversely
affected and/or Algos may not be able to establish and maintain price levels
sufficient for the realization of an appropriate return on our investment.
IF ALGOS INCURS INDEMNIFICATION LIABILITY, OR A PRODUCTS LIABILITY SUIT IS
SUCCESSFULLY PROSECUTED AGAINST US, WE MAY NOT HAVE SUFFICIENT FUNDS TO PAY THE
RESULTING LIABILITY.
Algos will be exposed to potential product liability risks, which are
inherent in the testing, manufacturing and marketing of human therapeutic
products. In addition, Algos is contractually obligated under certain of our
license agreements to indemnify the individuals and/or institutions from whom we
have licensed the technology against claims relating to the manufacture and sale
of the
4
<PAGE>
<PAGE>
products to be sold by Algos. Algos' indemnification liability, as well as
direct liability to consumers for any defects or health risks in the products
sold, could expose Algos to substantial losses which would reduce earnings and
funds available for research and development activities.
Algos currently carries certain liability insurance for our clinical trial
activities but does not have product liability insurance covering the commercial
use of our products. We plan to purchase such product liability insurance as we
deem appropriate prior to marketing our products. McNeil Consumer Products
Company is required by its license agreement to maintain product liability
insurance and may self-insure to cover its indemnification obligations to
Algos. However, there can be no assurance that Algos will be able to obtain or
maintain such insurance on acceptable terms or that any insurance obtained will
provide adequate coverage against potential liabilities.
IF THE MCNEIL LICENSE AGREEMENT IS TERMINATED AND ALGOS DESIRES TO DEVELOP AND
COMMERCIALIZE ITS OVER-THE-COUNTER PRODUCTS, ALGOS MAY BE FORCED TO DO SO ITSELF
WHICH MAY REDUCE PROFITS.
We are relying on McNeil to commercialize products involving acetaminophen,
ibuprofen and certain other over-the-counter pain relievers. Acetaminophen is
the active ingredient in Tylenol and ibuprofen is the active ingredient in
Motrin, both of which are manufactured by McNeil. If the agreement with McNeil
is terminated, then in the event that we desire to develop and commercialize our
products, we may be forced to do so ourselves. Because Algos does not have the
same level of resources as McNeil, this may reduce any potential future revenues
we may otherwise generate.
The license agreement dated June 26, 1996 with McNeil Consumer Products
Company extends until the later of the expiration of Algos' patent rights or ten
years from the date of execution, provided that the agreement is terminable:
by either party in the event of a breach by the other party upon 90 days
notice or upon certain events of bankruptcy;
by McNeil Consumer Products Company, at any time upon 60 days notice;
and
by Algos upon certain other circumstances.
IF ALGOS' COMPETITORS SUCCEED IN DEVELOPING COMPETING TECHNOLOGIES MORE RAPIDLY
THAN ALGOS, THE PRODUCTS WE ARE DEVELOPING MAY BE RENDERED OBSOLETE WHICH WOULD
PREVENT US FROM SUCCESSFULLY COMPETING IN OUR TARGET MARKETS.
As a development stage company, Algos' success will largely depend upon its
ability to successfully achieve market share at the expense of existing and
established products in Algos' target markets. A number of pharmaceutical
companies are developing pain relief products. Many of Algos' competitors have a
significantly higher degree of brand name recognition and substantially more
financial resources than those of Algos. They also may have greater research and
development capacities, experience, recognition and marketing, financial and
managerial resources than Algos. Accordingly, if Algos' competitors succeed in
developing competing technologies and obtaining FDA approval for products more
rapidly than Algos, Algos products or technologies may be rendered
non-competitive or obsolete in which case we would be unable to compete in our
target market.
5
<PAGE>
<PAGE>
A THIRD PARTY MAY HAVE DIFFICULTY SUCCESSFULLY MOUNTING A TAKEOVER BID FOR
CONTROL OF ALGOS WHICH COULD PREVENT YOU FROM MAXIMIZING THE VALUE OF YOUR ALGOS
COMMON STOCK AND COULD MAKE YOUR INVESTMENT LESS LIQUID.
The ownership of Algos is concentrated, with a small group of stockholders,
directors, officers and related investors owning approximately 40% of the common
stock. These stockholders, if they acted together, would have the ability to
influence significantly the election of Algos' directors as well as the
management and policies of Algos. This concentration of ownership may have the
effect of delaying or preventing a change of control of Algos. Certain other
provisions of Algos' Amended and Restated Certificate of Incorporation could
also have the effect of delaying or preventing changes of control or management
of Algos, which could adversely affect the market price and liquidity of our
common stock. In addition, Algos is subject to the anti-takeover provisions of
Section 203 of the Delaware General Corporation Law, which prohibits Algos from
engaging in a "business combination" with an "interested stockholder" for a
period of three years after the date of the transaction in which the person
first becomes an "interested stockholder," unless the business combination is
approved in a prescribed manner. The application of these provisions could have
the effect of delaying or preventing a change of control of Algos and could make
your investment less liquid.
IF WE, OUR CONTRACTORS OR OTHER ENTITIES ARE UNABLE TO ADEQUATELY ADDRESS THE
POTENTIAL DISRUPTIONS TO COMPUTER SYSTEMS THAT MAY OCCUR DUE TO THE ADVENT OF
THE YEAR 2000, WE MAY NOT BE ABLE TO EFFECTIVELY DEVELOP OR COMMERCIALIZE OUR
PRODUCTS.
A potential problem exists for all companies that rely on computers as the
year 2000 approaches. Computer software applications and systems that use only
the last two digits of a year to refer to a year may not properly recognize the
year 2000. This could cause a disruption of our operations, including, among
other things, a temporary inability to engage in normal business activities.
Because new development projects have not yet commenced and because we have not
completed our preparations for the commercialization and marketing of our
products, our assessment of our readiness with respect to the potential year
2000 computer problem is not complete.
For example, with respect to product development activities at Algos, if
certain data management and statistical applications do not function properly,
the analysis and reporting of study results could be delayed and the timing of
subsequent development activities and regulatory filings could be adversely
affected.
Algos may make significant additions to and changes in its existing computer
software applications and systems and/or the use of these systems in
anticipation of the possible commercialization of MorphiDex'r'. If Algos makes
any of these additions or changes, it would affect Algos' exposure to the
potential year 2000 computer problem since Algos would become more reliant on
its computer software applications and systems. If FDA approval of MorphiDex'r'
is received in 1999, we expect to rapidly begin commercialization efforts. Algos
will place significant dependence on the third parties' computer systems for
purchasing, production, customer order entry and invoicing and other related
activities. A disruption in these systems could result in lost revenue from
inventory shortages, improper execution of customer orders and/or delays in the
resolution and collection of outstanding invoices.
As part of our development and commercialization efforts, we will ask our
outside vendors, manufacturers, suppliers and service providers whether they
and/or any additional information systems and software that we acquire from them
are year 2000 compliant. However, these parties may be unable or unwilling to
make assurances of their year 2000 compliance. And, even if we do receive
assurances of year 2000 compliance, the parties making the assurances may not in
fact be year 2000 compliant. In the event any of our outside vendors,
manufacturers, suppliers
6
<PAGE>
<PAGE>
and service providers are not year 2000 compliant, we will likely be prevented
from developing or commercializing some or all of our products in a timely or
efficient manner.
7
